Plant Name: Amomum tsao-ko
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; DRD4; | |
| NPSR1; CXCR1; | |
| ALPI; RECQL; PLA2G1B; TDP1; PTGES; PIK3R1; GLO1; HPGD; MPO; AKR1B1; HSD17B2; HSD17B10; ALOX15; NOS2; ALDH1A1; ALOX12; NOX4; USP2; PYGL; POLB; | |
| GAA; | |
| AKT1; MET; CSNK2A1; DAPK1; FLT3; NEK6; PKN1; NEK2; CAMK2B; SRC; IGF1R; PTK2; AURKB; PRKCE; GSK3B; CDK1; MAPK1; EGFR; PIM1; NUAK1; ALK; FYN; AXL; KDR; | |
| CA12; CA7; CA3; CA14; CA5B; CA1; CA13; CA4; CA6; CA2; CA9; CA5A; | |
| NR1H4; | |
| PPARA; PPARG; PPARD; | |
| KDM4E; | |
| MAOA; ALOX5; XDH; | |
| MMP13; MMP3; MMP2; MMP9; ANPEP; | |
| BACE1; | |
| STAT6; HIF1A; NFKB1; TP53; | |
| EP300; | |
| ABCC1; ABCG2; | |
| NFE2L2; LMNA; MAPT; FABP3; F3; THPO; HTT; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Bromodomain | EP300 | Histone acetyltransferase p300 | Q09472 | CHEMBL3784 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOS2 | Nitric oxide synthase, inducible | P35228 | CHEMBL4481 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PTGES | Prostaglandin E synthase | O14684 | CHEMBL5658 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | ANPEP | Aminopeptidase N | P15144 | CHEMBL1907 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | PRKCE | Protein kinase C epsilon | Q02156 | CHEMBL3582 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | NFE2L2 | Nuclear factor erythroid 2-related factor 2 | Q16236 | CHEMBL1075094 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.634E-12 | 4.991E-10 | ALPI, ANPEP, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, EP300, GLO1, MMP13, MMP2, MMP3, MMP9, NR1H4, PPARA, PPARD, PPARG, TP53 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.025E-11 | 6.528E-09 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP3A4, NOS2, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.812E-11 | 9.793E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP3A4, MPO, NOS2, NOX4, SRC |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.061E-11 | 1.158E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.122E-10 | 2.003E-08 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, EGFR, FLT3, FYN, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PRKCE, PTK2, PYGL, RECQL, SRC, TP53 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.230E-10 | 9.759E-08 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 7.489E-10 | 1.137E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.047E-09 | 1.519E-07 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, EGFR, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1, PRKCE |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.375E-09 | 1.959E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 5.235E-09 | 6.868E-07 | AXL, EGFR, F3, FYN, MET, NOX4, PIK3R1, PTK2, SRC, THPO |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 1.155E-08 | 1.428E-06 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, PRKCE, SRC |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.644E-08 | 1.911E-06 | AURKB, CA2, CA7, EGFR, FYN, HIF1A, HTT, KDR, MAPK1, NEK2, NPSR1, NR1H4, PLA2G1B, PRKCE, SRC |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.024E-08 | 2.283E-06 | AURKB, CA2, CA7, EGFR, HIF1A, HTT, MAPK1, NEK2, NPSR1, NR1H4, PLA2G1B |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.305E-08 | 2.535E-06 | ABCG2, AKT1, ALK, APP, CAMK2B, CSNK2A1, DAPK1, DRD4, EGFR, FLT3, FYN, HPGD, HTT, IGF1R, KDR, MAPK1, MAPT, MET, MMP9, NFKB1, NOS2, PPARG, PYGL, STAT6, TP53, USP2, XDH |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 5.670E-08 | 5.663E-06 | AKT1, HIF1A, LMNA, NFE2L2, PPARD, PRKCE, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.786E-08 | 5.753E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.326E-07 | 1.213E-05 | EGFR, FYN, IGF1R, KDR, PTK2, SRC |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.371E-07 | 1.249E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.989E-07 | 2.456E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.989E-07 | 2.456E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 4.641E-07 | 3.662E-05 | AKT1, CYP1A2, EGFR, MAPK1, MMP9 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 4.641E-07 | 3.662E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 6.476E-07 | 4.896E-05 | AKR1B1, AXL, CDK1, CYP1B1, NFE2L2, STAT6 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.082E-06 | 7.775E-05 | ALOX12, ALOX15, ALOX5, HPGD |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.126E-06 | 8.063E-05 | CA2, CA7, FYN, HTT, KDR, NPSR1, PLA2G1B, PRKCE, SRC |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.257E-06 | 8.859E-05 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 1.447E-06 | 1.007E-04 | AKT1, AXL, FYN, MAPK1, PIK3R1, PRKCE, SRC |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 1.474E-06 | 1.022E-04 | EP300, GSK3B, HIF1A, HTT, NUAK1, TP53 |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 1.484E-06 | 1.023E-04 | AKT1, FFAR1, HIF1A, NOX4, NR1H4, PIK3R1, PPARG, PYGL |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.668E-06 | 1.134E-04 | AKT1, APP, CYP1A1, CYP1B1, EGFR, FLT3, MAPK1, NFKB1, NOX4, PPARG, SRC |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.742E-06 | 1.167E-04 | AXL, FYN, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.952E-06 | 1.292E-04 | CYP19A1, FFAR4, NFKB1, NR1H4, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 2.069E-06 | 1.357E-04 | CA3, CDK1, FYN, HPGD, POLB, PRKCE, TP53 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 2.398E-06 | 1.536E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3, PPARG |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.505E-06 | 1.591E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.505E-06 | 1.591E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 2.676E-06 | 1.675E-04 | AKT1, AURKB, CDK1, CYP1A1, MPO, NFE2L2, NOX4, POLB, TP53 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.489E-06 | 2.128E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.123E-06 | 2.990E-04 | CYP1A1, CYP1A2, CYP1B1, NFE2L2 |
| CC | GO:0044464; cell part | GO:0005641; nuclear envelope lumen | 6.962E-06 | 3.958E-04 | ALOX5, APP, PTGES |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 7.292E-06 | 4.114E-04 | ALOX15, APP, EGFR, FFAR4, KDR, NOX4, SRC, THPO |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 9.913E-06 | 5.465E-04 | AKR1B1, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APP, AURKB, CA1, CA13, CA2, CA3, CA7, CAMK2B, CDK1, CSNK2A1, EP300, FABP3, FLT3, FYN, GLO1, GSK3B, HIF1A, HPGD, HTT, LMNA, MAPK1, MAPT, NEK2, NEK6, NFE2L2, NFKB1, NOS2, PIK3R1, PIM1, PKN1, PLA2G1B, PPARG, PRKCE, PTK2, PYGL, SRC, STAT6, TP53, XDH |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 1.040E-05 | 5.650E-04 | APP, EGFR, MAPT |
| MF | GO:0005488; binding | GO:0032052; bile acid binding | 1.040E-05 | 5.650E-04 | NR1H4, PLA2G1B, PYGL |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.342E-05 | 7.077E-04 | AXL, FYN, IGF1R, PIK3R1 |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 1.405E-05 | 7.390E-04 | AKT1, DAPK1, FYN, HTT, LMNA, SRC |
| BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 1.481E-05 | 7.733E-04 | PPARG, SRC, TP53 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.656E-05 | 8.545E-04 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.504E-26 | 1.416E-21 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.009E-05 | 1.017E-03 | CSNK2A1, HIF1A, KDR, MAPT |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 2.029E-05 | 1.023E-03 | GSK3B, HTT, MAPT |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 2.122E-05 | 1.067E-03 | FLT3, FYN, KDR, PPARD, PTK2 |
| BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 2.455E-05 | 1.218E-03 | FFAR1, HIF1A, NR1H4, PPARD, PRKCE |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.548E-05 | 1.244E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.548E-05 | 1.244E-03 | ALOX12, ALOX15 |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 3.467E-05 | 1.645E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 3.491E-05 | 1.649E-03 | CA2, CA7, PRKCE |
| BP | GO:0008152; metabolic process | GO:0006809; nitric oxide biosynthetic process | 3.491E-05 | 1.649E-03 | AKT1, CYP1B1, NOS2 |
| MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 3.618E-05 | 1.691E-03 | NEK6, NFE2L2, PPARA, TP53 |
| BP | GO:0009987; cellular process | GO:1900034; regulation of cellular response to heat | 4.777E-05 | 2.145E-03 | CAMK2B, EP300, GSK3B, MAPK1, MAPT |
| BP | GO:0009987; cellular process | GO:0038096; Fc-gamma receptor signaling pathway involved in phagocytosis | 5.250E-05 | 2.333E-03 | FYN, MAPK1, PIK3R1, PRKCE, PTK2, SRC |
| BP | GO:0050896; response to stimulus | GO:0009612; response to mechanical stimulus | 6.114E-05 | 2.647E-03 | AKT1, EGFR, FYN, MPO, NFKB1, PPARG, SRC |
| BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 6.605E-05 | 2.837E-03 | AKT1, NFE2L2, NR1H4, PIK3R1 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 6.652E-05 | 2.851E-03 | AKR1B1, AKT1, ALOX5, AURKB, CAMK2B, CDK1, CSNK2A1, EP300, GSK3B, HIF1A, HPGD, HTT, LMNA, MAPK1, NEK2, NEK6, NFE2L2, NFKB1, NR1H4, NUAK1, PIM1, PKN1, POLB, PPARA, PPARD, PPARG, RECQL, SRC, STAT6, TP53, USP2 |
| BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 7.237E-05 | 3.068E-03 | AKT1, HIF1A, KDR, NFE2L2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 7.618E-05 | 3.184E-03 | CA2, CA7 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 7.632E-05 | 3.184E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 7.618E-05 | 3.184E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 7.618E-05 | 3.184E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 7.618E-05 | 3.184E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 7.813E-05 | 3.231E-03 | AKR1B1, ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP3A4, MPO, PLA2G1B, PTGES |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 7.819E-05 | 3.231E-03 | AKT1, CA5A, CA5B, CDK1, CYP1A1, CYP1B1, FYN, GSK3B, HSD17B10, MAOA, MAPK1, MMP2, MPO, NFKB1, NOX4, PRKCE, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 7.913E-05 | 3.263E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 8.178E-05 | 3.322E-03 | CYP1A1, PPARD, PPARG |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 8.178E-05 | 3.322E-03 | AURKB, MAPK1, NEK2 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 8.178E-05 | 3.322E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 8.917E-05 | 3.556E-03 | ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B |
| BP | Unclassified; | GO:1905953; negative regulation of lipid localization | 9.399E-05 | 3.728E-03 | AKT1, NFKB1, PPARA, PPARG |
| BP | GO:0050896; response to stimulus | GO:0071496; cellular response to external stimulus | 9.681E-05 | 3.833E-03 | AKT1, AXL, EGFR, MAPK1, NFE2L2, NFKB1, PPARG, TP53 |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 1.054E-04 | 4.151E-03 | AKR1B1, APP, CA4, EGFR, HTT, NOS2, NOX4, PPARG, PRKCE, PTGES, SRC, USP2 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.108E-04 | 4.339E-03 | NR1H4, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:1901565; organonitrogen compound catabolic process | 1.140E-04 | 4.425E-03 | AKT1, ANPEP, AURKB, BACE1, CDK1, CYP3A4, GSK3B, HSD17B10, MAOA, NFE2L2, NOS2, TP53, XDH |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.231E-04 | 4.742E-03 | APP, BACE1, EGFR, FYN, KDR, MAPK1, SRC, STAT6 |
| BP | GO:0009987; cellular process | GO:0051493; regulation of cytoskeleton organization | 1.254E-04 | 4.823E-03 | ALOX15, GSK3B, MAPK1, MAPT, MET, NEK2, NOX4, PIK3R1, PRKCE, PTK2 |
| BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 1.340E-04 | 5.103E-03 | ALOX12, APP, AXL, EGFR, FFAR4, GSK3B, HIF1A, LMNA, NFE2L2, NFKB1, NR1H4, PIK3R1, PPARD, PPARG, PTK2, XDH |
| BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 1.340E-04 | 5.103E-03 | ALOX12, CYP1B1, F3, HIF1A, KDR, NFE2L2 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 1.419E-04 | 5.298E-03 | DRD4, PPARA, PPARG, TP53, USP2 |
| BP | GO:0051179; localization | GO:0015909; long-chain fatty acid transport | 1.508E-04 | 5.573E-03 | DRD4, FABP3, PLA2G1B, PPARG |
| BP | GO:0050896; response to stimulus | GO:0090303; positive regulation of wound healing | 1.508E-04 | 5.573E-03 | F3, NFE2L2, PPARD, PRKCE |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 1.519E-04 | 5.586E-03 | EGFR, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.519E-04 | 5.586E-03 | CYP1A1, CYP1A2 |
| BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 1.576E-04 | 5.730E-03 | CA2, NFE2L2, SRC |
| BP | GO:0008152; metabolic process | GO:0005977; glycogen metabolic process | 1.622E-04 | 5.847E-03 | AKT1, GAA, GSK3B, PYGL |
| BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 1.710E-04 | 6.106E-03 | AKT1, APP, AXL, CA2, CAMK2B, FYN, HIF1A, KDR, MAPT, NFE2L2, NFKB1, PPARD, PPARG, THPO |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 1.742E-04 | 6.147E-03 | CDK1, EGFR, IGF1R, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0050730; regulation of peptidyl-tyrosine phosphorylation | 1.756E-04 | 6.167E-03 | APP, EGFR, FLT3, FYN, PRKCE, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:0000226; microtubule cytoskeleton organization | 1.771E-04 | 6.191E-03 | AURKB, CDK1, HTT, LMNA, MAPT, NEK2, NEK6, PTK2 |
| BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 1.792E-04 | 6.255E-03 | GSK3B, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.818E-04 | 6.305E-03 | HPGD, MMP2, MMP9 |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 1.869E-04 | 6.448E-03 | ABCG2, AKT1, AXL, CAMK2B, EGFR, FLT3, HIF1A, HPGD, MAPT, NFKB1, NOS2, PIK3R1, PPARD, PPARG, PYGL, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0042176; regulation of protein catabolic process | 1.912E-04 | 6.587E-03 | AKT1, CDK1, CSNK2A1, EGFR, FYN, GSK3B, NFE2L2, NOS2, PTK2 |
| BP | GO:0007610; behavior | GO:0007611; learning or memory | 1.951E-04 | 6.705E-03 | APP, EGFR, FYN, HIF1A, HTT, MAPK1, MAPT |
| BP | GO:0065007; biological regulation | GO:0050878; regulation of body fluid levels | 1.984E-04 | 6.794E-03 | AKR1B1, ALOX12, F3, FYN, HIF1A, MET, NFE2L2, PRKCE, XDH |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 2.084E-04 | 7.101E-03 | FLT3, HIF1A, KDR, MAPK1, PKN1, POLB |
| BP | GO:0051179; localization | GO:0032368; regulation of lipid transport | 2.142E-04 | 7.277E-03 | AKT1, CYP19A1, NFKB1, PPARA, PPARG |
| BP | GO:0009987; cellular process | GO:0010822; positive regulation of mitochondrion organization | 2.222E-04 | 7.538E-03 | GSK3B, HIF1A, HTT, KDR, MMP9, TP53 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 2.237E-04 | 7.576E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 2.289E-04 | 7.741E-03 | NR1H4, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 2.372E-04 | 7.910E-03 | CYP1A1, CYP1A2, PPARG |
| BP | GO:0008152; metabolic process | GO:0036003; positive regulation of transcription from RNA polymerase II promoter in response to stress | 2.372E-04 | 7.910E-03 | HIF1A, NFE2L2, TP53 |
| BP | GO:0065007; biological regulation | GO:0051091; positive regulation of DNA binding transcription factor activity | 2.394E-04 | 7.970E-03 | AKT1, ALK, APP, EP300, NFKB1, PLA2G1B, PPARG |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 2.516E-04 | 8.211E-03 | AKT1, APP, EGFR, FYN, KDR, NOX4, SRC |
| BP | GO:0009987; cellular process | GO:1902905; positive regulation of supramolecular fiber organization | 2.521E-04 | 8.211E-03 | ALOX15, APP, MAPT, MET, NOX4, PRKCE |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 2.523E-04 | 8.211E-03 | ALOX12, ALOX15 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 2.523E-04 | 8.211E-03 | PPARA, PPARG |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 2.682E-04 | 8.575E-03 | NR1H4, PIM1, PPARA, PPARD, PPARG, SRC |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 2.686E-04 | 8.575E-03 | HIF1A, PPARD, TP53 |
| MF | Unclassified; | GO:0004872; receptor activity | 2.682E-04 | 8.575E-03 | ALK, ANPEP, AXL, CXCR1, DRD4, EGFR, F3, FFAR1, FFAR4, FLT3, HPGD, IGF1R, KDR, MET, NPSR1, NR1H4, PPARA, PPARD, PPARG |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 2.766E-04 | 8.805E-03 | AKT1, AURKB, CSNK2A1, EP300, NUAK1, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 2.877E-04 | 9.105E-03 | ALOX15, EGFR, MMP13, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 3.025E-04 | 9.461E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0051179; localization | GO:0032309; icosanoid secretion | 3.025E-04 | 9.461E-03 | DRD4, NOS2, PLA2G1B |
| BP | GO:0007610; behavior | GO:0007626; locomotory behavior | 3.028E-04 | 9.461E-03 | ALK, APP, DRD4, GAA, PRKCE, USP2 |
| BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 3.118E-04 | 9.703E-03 | AXL, FLT3, HIF1A, PKN1, POLB |
| BP | GO:0008152; metabolic process | GO:0006650; glycerophospholipid metabolic process | 3.119E-04 | 9.703E-03 | ALOX15, ALPI, CSNK2A1, EGFR, FYN, MET, PIK3R1, PLA2G1B |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 3.118E-04 | 9.703E-03 | EP300, GSK3B, NFE2L2, PPARA, TP53 |
| BP | GO:0065007; biological regulation | GO:0051881; regulation of mitochondrial membrane potential | 3.135E-04 | 9.737E-03 | AKT1, KDR, MAPT, SRC |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.675E-18 | 3.883E-15 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.740E-17 | 1.994E-14 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.782E-25 | 1.104E-22 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 6.117E-14 | 5.842E-12 | GSK3B; NOS2; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; EGFR; NFKB1; PTK2; IGF1R; AKT1; EP300; MAPK1; PPARG; MET; TP53; PPARD |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.212E-12 | 7.715E-11 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; MMP9; PTK2; EGFR; IGF1R; KDR; AKT1; MAPK1; TP53; MET |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 8.081E-11 | 3.858E-09 | CAMK2B; NOS2; AKT1; EP300; MAPK1; PIK3R1; HIF1A; EGFR; NFKB1; IGF1R |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.151E-10 | 1.968E-08 | GSK3B; AKT1; EP300; MAPK1; PIK3R1; TP53; EGFR; NFKB1; IGF1R |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.278E-09 | 3.133E-08 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A; EGFR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.070E-09 | 3.133E-08 | DAPK1; SRC; MMP2; MAPK1; MMP9; TP53; EGFR |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 4.422E-09 | 8.446E-08 | GSK3B; SRC; KDR; AKT1; MAPK1; FYN; PIK3R1; MET; PTK2; EGFR; IGF1R |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.312E-09 | 3.133E-08 | HPGD; FLT3; MMP3; PPARG; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.871E-09 | 6.093E-08 | CSNK2A1; SRC; EP300; MAPK1; FYN; MET; EGFR; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.057E-08 | 1.682E-07 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; EGFR; PTK2 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.181E-08 | 1.735E-07 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PPARD |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.455E-08 | 4.125E-07 | PRKCE; MMP2; PIM1; AKT1; MAPK1; PIK3R1; F3; NFKB1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 3.012E-08 | 3.836E-07 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; EGFR; IGF1R |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.163E-08 | 4.678E-07 | SRC; AKT1; EP300; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.154E-08 | 2.938E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; PTGES |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.087E-07 | 9.887E-07 | GSK3B; KDR; AKT1; MAPK1; PIK3R1; PKN1; TP53; MET; PTK2; EGFR; NFKB1; IGF1R |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.051E-07 | 9.887E-07 | NOS2; PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PYGL; CYP3A4; CYP19A1; HSD17B10; CYP2C9; CYP2C8; ANPEP; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; ALPI; XDH; PTGES |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 5.618E-08 | 5.962E-07 | AKT1; MAPK1; PIK3R1; TP53; MET; EGFR; IGF1R |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 7.779E-08 | 7.820E-07 | CYP2C9; APP; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; ALOX12 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.168E-07 | 1.014E-06 | GSK3B; SRC; AKT1; EP300; MAPK1; PIK3R1; TP53; HIF1A |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.140E-09 | 8.926E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.293E-07 | 1.685E-06 | ABCC1; PRKCE; PIM1; CYP1B1; EP300; MAPK1; TP53; MMP9; MET; EGFR; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.331E-07 | 1.106E-06 | ABCC1; PRKCE; AKT1; MAPK1; FYN; PIK3R1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.947E-07 | 2.084E-06 | GSK3B; AKT1; MAPK1; PIK3R1; PPARA; TP53; EGFR; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 5.625E-07 | 3.466E-06 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.012E-07 | 1.537E-06 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; EGFR |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.583E-07 | 1.260E-06 | ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.159E-07 | 2.155E-06 | ALK; AKT1; MAPK1; PIK3R1; TP53; EGFR |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.749E-06 | 9.027E-06 | PLA2G1B; KDR; AKT1; MAPK1; PIK3R1; MET; EGFR; NFKB1; IGF1R |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.082E-06 | 5.905E-06 | GSK3B; PRKCE; AKT1; PIK3R1; PYGL; PPARA; NFKB1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 5.296E-07 | 3.372E-06 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.068E-06 | 1.039E-05 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 8.497E-07 | 4.773E-06 | AKT1; MAPK1; PIK3R1; TP53; EGFR; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 3.860E-06 | 1.843E-05 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 6.817E-06 | 2.960E-05 | GSK3B; CSNK2A1; CDK1; AKT1; EP300; PIK3R1; TP53; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.427E-06 | 7.571E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 8.497E-07 | 4.773E-06 | AKT1; EP300; MAPK1; PIK3R1; MET; HIF1A |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 7.594E-06 | 3.223E-05 | POLB; SRC; CDK1; EP300; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 4.760E-06 | 2.164E-05 | GSK3B; CSNK2A1; AKT1; FYN; PIK3R1; TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 7.755E-07 | 4.629E-06 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 9.376E-06 | 3.893E-05 | SRC; KDR; AKT1; MAPK1; PIK3R1; MET; EGFR; IGF1R |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.906E-07 | 2.573E-06 | CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 6.819E-06 | 2.960E-05 | AKT1; PPARG; PIK3R1; TP53; NFKB1; IGF1R |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 4.064E-06 | 1.893E-05 | NOS2; AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.075E-06 | 1.506E-05 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.222E-05 | 4.965E-05 | GSK3B; AKT1; MAPK1; FYN; PIK3R1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.684E-05 | 6.565E-05 | MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 2.751E-05 | 9.914E-05 | CAMK2B; NOS2; SRC; AKT1; EP300; MAPK1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 2.511E-05 | 9.223E-05 | NOS2; ALOX5; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.595E-05 | 1.781E-04 | CAMK2B; AKT1; EP300; MAPK1; PIK3R1; PPARA; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.557E-05 | 2.053E-04 | LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 4.722E-05 | 1.555E-04 | AKT1; MAPK1; PPARG; FYN; PIK3R1; NFKB1 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 4.926E-05 | 1.595E-04 | AKT1; EP300; MAPK1; PIK3R1; EGFR; IGF1R |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 7.095E-05 | 2.186E-04 | CAMK2B; GSK3B; CSNK2A1; EP300; TP53; PPARD |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 7.667E-05 | 2.324E-04 | CXCR1; AKT1; MAPK1; FYN; PIK3R1; EGFR |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.278E-04 | 3.644E-04 | THPO; PIM1; AKT1; EP300; STAT6; PIK3R1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.941E-05 | 1.003E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.322E-05 | 5.260E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.081E-05 | 7.948E-05 | CXCR1; SRC; MET; EGFR; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.941E-05 | 1.003E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.207E-04 | 3.494E-04 | CDK1; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.207E-04 | 3.494E-04 | CAMK2B; SRC; PRKCE; ALOX12; PIK3R1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.235E-05 | 8.369E-05 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 8.493E-05 | 2.535E-04 | CAMK2B; SRC; MMP2; MAPK1; EGFR |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.786E-04 | 4.806E-04 | BACE1; APP; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.229E-04 | 5.752E-04 | GSK3B; AKT1; EP300; MAPK1; PIK3R1; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.794E-04 | 7.021E-04 | POLB; GSK3B; AKT1; EP300; PIK3R1; TP53; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.941E-05 | 1.003E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.392E-04 | 3.853E-04 | AKT1; MAPK1; PIK3R1; HIF1A; EGFR |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.392E-04 | 3.853E-04 | CAMK2B; AKT1; EP300; PYGL; PPARA |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 2.167E-04 | 5.670E-04 | CAMK2B; AKT1; MAPK1; FYN; PIK3R1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.597E-04 | 4.359E-04 | NOS2; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 3.359E-04 | 8.333E-04 | SRC; AKT1; MAPK1; FYN; PIK3R1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 8.870E-04 | 1.925E-03 | GSK3B; AKT1; PIK3R1; PPARA; NFKB1 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 6.724E-04 | 1.493E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 6.104E-04 | 1.372E-03 | GSK3B; AKT1; MAPK1; PIK3R1; PYGL |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 4.042E-04 | 9.530E-04 | GSK3B; MAPK1; FYN; MET; PTK2 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 4.342E-04 | 9.992E-04 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.734E-03 | 3.451E-03 | CXCR1; SRC; KDR; MET; EGFR; IGF1R |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.603E-03 | 3.258E-03 | AKT1; MAPK1; MAPT; TP53; EGFR; NFKB1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.086E-03 | 2.305E-03 | CAMK2B; SRC; MAPK1; PIK3R1; EGFR |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.946E-03 | 3.794E-03 | CXCR1; THPO; FLT3; KDR; MET; EGFR |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.176E-03 | 4.198E-03 | CSNK2A1; CDK1; EP300; TP53; NFKB1 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 4.064E-03 | 7.323E-03 | SRC; MAPK1; PIK3R1; PTK2; EGFR |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.483E-03 | 3.046E-03 | CAMK2B; GSK3B; EP300; MAPK1 |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 1.503E-02 | 2.412E-02 | HTT; EP300; PPARG; TP53 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 3.153E-03 | 5.962E-03 | CAMK2B; CDK1; MAPK1; IGF1R |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.838E-03 | 3.619E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.483E-03 | 3.046E-03 | NOS2; PIK3R1; NFKB1; PTK2 |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 4.874E-03 | 8.619E-03 | CSNK2A1; SRC; PRKCE; AKT1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 3.246E-03 | 6.019E-03 | AKT1; PPARG; PIK3R1; IGF1R |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 3.246E-03 | 6.019E-03 | GSK3B; CDK1; EP300; TP53 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.134E-03 | 2.379E-03 | PRKCE; AKT1; MAPK1; PIK3R1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 9.224E-03 | 1.526E-02 | PRKCE; AKT1; MAPK1; PIK3R1 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 6.075E-03 | 1.027E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 2.715E-03 | 5.185E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 2.874E-02 | 4.323E-02 | MAPK1; FYN; PIK3R1 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 3.471E-04 | 8.500E-04 | AKT1; MAPK1; FYN; PIK3R1 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 2.121E-02 | 3.293E-02 | PLA2G1B; PRKCE; MAPK1 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 9.225E-04 | 1.980E-03 | SRC; CDK1; MAPK1; EGFR |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 8.463E-04 | 1.858E-03 | NOS2; MAPK1; PKN1; NFKB1 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 5.857E-04 | 1.332E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.142E-04 | 5.670E-04 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 3.671E-04 | 8.876E-04 | FABP3; PPARG; PPARA; PPARD |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 9.268E-03 | 1.526E-02 | THPO; FLT3; ANPEP |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.095E-04 | 9.539E-04 | CA2; NR1H4; CYP3A4; ABCG2 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 5.537E-03 | 9.614E-03 | NOS2; MAPK1; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 5.969E-03 | 1.018E-02 | NOS2; MAPK1; NFKB1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 4.925E-03 | 8.630E-03 | AKT1; PPARA; NFKB1 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 4.175E-03 | 7.453E-03 | CAMK2B; EP300; MAPK1 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 3.828E-03 | 7.031E-03 | AKT1; PIK3R1; IGF1R |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 3.083E-02 | 4.530E-02 | AKT1; PIK3R1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 4.000E-03 | 7.275E-03 | SRC; MAPK1; NFKB1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.186E-02 | 4.645E-02 | MAPK1; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.326E-05 | 1.450E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 2.983E-02 | 4.451E-02 | GSK3B; TP53 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 3.083E-02 | 4.530E-02 | GAA; PYGL |
| hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 2.500E-02 | 3.789E-02 | NOS2; MAOA |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.407E-02 | 3.678E-02 | MAOA; NFKB1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.052E-02 | 3.213E-02 | AKT1; PIK3R1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.682E-03 | 3.381E-03 | PRKCE; MAPK1; PIK3R1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.139E-02 | 3.294E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.967E-02 | 3.105E-02 | ABCC1; ABCG2 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.565E-02 | 2.492E-02 | MAPK1; PIK3R1 |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 1.273E-02 | 2.060E-02 | MAPK1; FYN |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.800E-04 | 9.073E-04 | MAPK1; PPARG; TP53 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 9.455E-03 | 1.544E-02 | GAA; AKR1B1 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 7.702E-03 | 1.290E-02 | MAPK1; EGFR |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.623E-03 | 9.675E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.354E-04 | 5.995E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; EGFR |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | NFE2L2; PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; EGFR; APP; KDR |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; F3; EGFR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; IGF1R; CDK1; NOS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; NFKB1; PPARG; PPARG; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR; ANPEP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| NA: NA | GIST | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; HIF1A; EGFR; CA9 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; NOS2 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARG; PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | NFE2L2; MET; IGF1R; IGF1R; EGFR; EGFR; AXL; KDR |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| I00-I99: Diseases of the circulatory system | Ischemic reperfusion injury | I00-I99 | PRKCE |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; PPARD |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; PRKCE |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; APP |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; NOS2 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| NA: NA | Dyslipidemia | NA | PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ALOX5; MMP3; CAMK2B |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; EGFR; EGFR; EGFR; TP53; KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; NOS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4 |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | NOS2 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Endotoxic shock | R57.8 | NOS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH; PPARG |
| NA: NA | Geographic retinal atrophy | NA | APP |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; KDR; KDR |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; FFAR1; GSK3B; PPARG |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; IGF1R; CYP19A1; CDK1; EGFR; EGFR; EGFR; CA9; KDR; KDR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic kidney disease | E11.22 | NOS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; EGFR; EGFR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; EGFR; EGFR; KDR; KDR; KDR; KDR |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; PTGES; MAPT; GSK3B; PPARG; PPARG; APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | NOS2 |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; EGFR; EGFR; TP53; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR; KDR; KDR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; FLT3; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; EGFR; TP53; CA9; KDR; KDR; KDR |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; CAMK2B; CYP3A4 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; NOS2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; MET; CSNK2A1; CA1; FLT3; FLT3; MMP2; SRC; IGF1R; PTK2; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; EGFR; PIM1; TP53; CA9; APP; KDR |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |